Acute acalculous cholecystitis in children

Dimitri Poddighe, Vitaliy Sazonov

Dimitri Poddighe, Vitaliy Sazonov, Department of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan

Vitaliy Sazonov, Pediatric Intensive Care Unit, UMC National Research Center for Mother and Child Health, Astana 010000, Kazakhstan

ORCID number: Dimitri Poddighe (0000-0001-6431-9334); Vitaliy Sazonov (0000-0003-0437-4694).

Author contributions: Poddighe D conceived and wrote the manuscript; Sazonov V contributed to the literature research and data collection.

Conflict-of-interest statement: The authors have no conflict of interest to declare.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Submitted manuscript

Corresponding author to: Dimitri Poddighe, MD, MSc, Assistant Professor, Department of Medicine, School of Medicine, Nazarbayev University, Kerei-Zhanibek Str. 5/1, Astana 010000, Kazakhstan. dimitri.poddighe@nu.edu.kz

Telephone: +7-700-2679413

Received: September 12, 2018

Peer-review started: September 12, 2018

First decision: October 8, 2018

Revised: October 11, 2018

Accepted: October 21, 2018

Article in press: October 21, 2018

Published online: November 21, 2018

Abstract

Acute acalculous cholecystitis (AAC) is the inflammatory disease of the gallbladder in the absence of gallstones. AAC is estimated to represent at least 50% to 70% of all cases of acute cholecystitis during childhood. Although this pathology was originally described in critically ill or post-surgical patients, most pediatric cases have been observed during several infectious diseases. In addition to cases caused by bacterial and parasitic infections, most pediatric reports after 2000 described children developing AAC during viral illnesses (such as Epstein-Barr virus and hepatitis A virus infections). Moreover, some pediatric cases have been associated with several underlying chronic diseases and, in particular, with immune-mediated disorders. Here, we review the epidemiological aspects of pediatric AAC, and we discuss etiology, pathophysiology and clinical management, according to the cases reported in the medical literature.

Key words: Acute acalculous cholecystitis; Children; Viral biliary disorders

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Acute acalculous cholecystitis (AAC) is the most frequent form of acute cholecystitis in children. In childhood, this disease has been described in critically ill or post-surgical patients, as it often occurs in adults, but most pediatric cases are actually caused by infectious diseases. In addition to bacterial and parasitic infections, most recent pediatric reports have described children developing AAC during viral illnesses, in particular, Epstein-Barr virus and hepatitis A virus infections. Moreover, some pediatric cases have been associated with non-infectious disorders, such as immune-mediated disorders. Therefore, the medical management presents significant differences compared to adult AAC.
INTRODUCTION

Acute cholecystitis is an inflammatory condition of the gallbladder, which is most commonly associated with the presence of gallstones. These cases are referred to as acute calculous cholecystitis (ACC); here, the obstruction of the cystic duct from small- and medium-sized gallstones that migrate from the gallbladder or from large gallstones that intermittently obstruct the neck of the gallbladder, is considered the main pathogenic moment. However, several clinical and experimental evidences from human and animal studies strongly suggest that biliary obstruction due to gallstones represents only the final event of a more complex pathological process, where the development of acute inflammation is due to the progression from an underlying chronic injury. Very briefly, cholecystitis can develop in the presence of lithogenic bile with high cholesterol concentrations, diffusing through the gallbladder wall and permitting the hydrophobic bile salts to increase the levels of oxidative stress and to trigger the inflammatory process.

These pathogenic mechanisms may be implicated even in some cases of acute AAC where no gallstones can be identified, but only gallbladder bile sludge. However, most cases of AAC are not associated with any pre-existing biliary disease and/or factors suggesting the presence of lithogenic bile, especially in the pediatric population. Indeed, AAC is the most frequent form of acute cholecystitis in children, whereas in adults it accounts for only 5%-10% of all cases. AAC is estimated to represent at least 50% to 70% of all cases of acute cholecystitis during childhood; of course, the remaining portion is represented by ACC, which is usually associated with hemolytic diseases or intestinal diseases that affect the entero-hepatic recirculation of biliary salts.

AAC can develop in a variety of clinical settings, suggesting the existence of several pathogenic mechanisms, which may have different weights according to the specific situation. However, those mechanisms can be traced back to two main types of gallbladder injury. One is the chemical injury from bile stasis; however, unlike ACC, the harmful effect on the gallbladder in AAC actually derives from impaired gallbladder emptying rather than altered bile composition. This is likely to be the main trigger in pediatric AAC cases due to some parasite infections obstructing the common bile duct (e.g., Ascaris lumbricoides infestation) or in rare congenital malformations of the gallbladder (e.g., multiseptated gallbladder, diaphragm of the gallbladder, choleodochal cyst, etc.). Moreover, bile stasis may be also a pathogenic component of AAC in children admitted to the pediatric intensive care unit (PICU) for different reasons. Indeed, the prolonged period of fasting (with oral feeding replaced by parenteral nutrition) and the use of opiates (inducing spams and/or dyskinesia of the sphincter of Oddi) interferes with gallbladder emptying.

A second important mechanism of gallbladder injury is local ischemia. The cystic artery is the chief source of blood supply to the gallbladder, in addition to the cystic duct, common hepatic duct and the upper part of the bile duct. The cystic artery can have different anatomical origins, but it usually arises from the right hepatic artery, which is one of the terminal branches of the proper hepatic artery. Importantly, the cystic artery is a terminal artery, meaning that it is the only supply of oxygenated blood to gallbladder tissues, which explains its major susceptibility to ischemic conditions in the presence of several underlying or concomitant diseases. The remarkable importance of the ischemic mechanism in AAC was demonstrated through a fundamental study by Hakala et al., published in 1997. Briefly, these authors compared angiographic and histological aspects of patients affected with ACC and AAC. The main gallbladder micro-angiographic findings in AAC were clearly different from those in gallstone-associated cholecystitis. The latter revealed a florid and dilated microcirculation (related to inflammation), whereas an irregular arterial/capillary network with absent or minimal venous filling characterized AAC. Importantly, AAC patients presented quite different underlying diseases (cardiac infarction - treated with emergency coronary bypass -, staphylococcal septicemia, septic shock and hypovolemic shock), which highlighted the fact that ischemic factors and/or tissue hypoxia are the common and final pathogenic mechanisms of gallbladder injury. Further studies confirmed these pathological aspects, and they likely have a prominent role even in AAC cases arising outside the PICU, like patients suffering from vasculitis or previously healthy children developing ACC during a concomitant infectious disease.

EPIDEMIOLOGY AND RISK FACTORS

Gallbladder disease is a relatively rare condition in children. Before 2000s, Tsakayannis et al. estimated only 1.3 pediatric cases for every 1000 cases of adult gallbladder disease. Nevertheless, the incidence of cholecystitis in children has increased over the last 20 years. For example, a recent study from Canada reported that the incidence of pediatric cholecystectomy increased from 8.8 to 13.0 per 10000 person-years from 1993 to 2012, and cholecystitis accounted for 9.3% of all pediatric procedures of the biliary tract.

As previously mentioned, AAC represents the most common form of cholecystitis in children (50%-70%), and it can arise in different clinical settings. According to this observation, AAC can be grouped into three main categories: (1) AAC associated with critical medical conditions, (2) AAC associated with underlying (non-critical) diseases, and (3) AAC arising in previously healthy children.

Acute acalculous cholecystitis in children with critical medical conditions

AAC has been described as a complication of several types of surgery. In adults, most reports of post-operative AAC followed interventions of open abdominal
Acute acalculous cholecystitis in children with non-critical medical conditions

This category includes those cases of AAC developing in patients with comorbidity, which is supposed to contribute to the occurrence of gallbladder disease. Indeed, there are many reports of AAC arising in the context of autoimmune/immune-mediated diseases, in particular vasculitis. Here, the systemic inflammation could also involve the gallbladder vasculature, leading to local ischemic injury[^5]. In Table 1, we listed all of the case reports describing AAC in children affected with immune-mediated diseases since 2000[^13-18].

Among these immunological conditions, Kawasaki disease received particular attention and detailed description. According to the large case series published by Yi et al[^19], which included 131 children with AAC, 26.7% of patients were affected with a systemic (non-infectious) disease, and most had Kawasaki disease (28 cases). Interestingly, these authors found that the presence of AAC in the acute phase of Kawasaki disease was statistically associated with the development of coronary complications, in addition to more severe clinical presentations[^20]. Previously, Chen et al[^21] studied the occurrence of gallbladder abnormalities (including AAC or hydrops) in children with Kawasaki disease, and they found higher rates of intravenous immunoglobulin resistance.

Additional reports of AAC associated with systemic (non-infectious) illnesses included malignancies (e.g., hemophagocytic lymphohistiocytosis, acute leukemias), renal diseases (e.g., end-stage renal disease) and genetic diseases (e.g., galactosemia, diabetes mellitus, cystic fibrosis[^16,10,22-24]).

Acute acalculous cholecystitis in previously healthy children

Most cases of pediatric AAC have been described in children without life-threatening conditions or underlying comorbidities. In this group, a large variety of infectious agents have been implicated in the pathogenesis of AAC, including viruses, bacteria, yeasts and parasites. Before 2000, most reports of infectious AAC referred to intestinal parasites (e.g., Ascaris lumbricoides), typhoid fever and leptospirosis[^6]. AAC can be one of the clinical manifestations of hepatobiliary ascariasis, characterized by the passage of worms from the duodenum to the biliary tract, leading to bile flow obstruction[^25]. Typhoid fever is a systemic infection caused by some Salmonella species, in particular Salmonella typhi. AAC in typhoid fever is usually a secondary complication depending on bacterial strain virulence or its resistance to treatment, especially in endemic areas. These bacteria reach the gallbladder through the blood stream and have been shown to have a tropism for the vesicular wall epithelium[^26]. Leptospirosis is a zoonotic infection sustained by several species of the genus Leptospira and, again, AAC derives from the direct localization of these bacteria in the gallbladder[^27].

However, after 2000 (probably due to the larger diffusion of the abdominal ultrasound), a multitude of publications have associated pediatric AAC with many types of infections, including several viral diseases. In Table 2, we listed all case reports or small case series describing infectious AAC in children, in whom a clear etiological diagnosis was achieved[^28-60].

Among AAC cases due to viral infections, many

---

**Table 1** Reported cases of non-infectious pediatric acute acalculous cholecystitis associated with immune-mediated disorders (2000-2018)

| Ref. | Age (yr) | Sex | Comorbidity | Clinical manifestations |
|------|----------|-----|-------------|------------------------|
| Basiratnia et al[^18], 2006 | 10 | M | Systemic lupus erythematosus | RUQ pain, fever, nausea, vomiting |
| Shin et al[^16], 2007 | 5 | M | Nephrotic syndrome | Abdominal pain, vomiting |
| Mendonça et al[^15], 2009 | 12 | F | Systemic lupus erythematosus | Abdominal pain, anorexia, weight loss, nausea, vomiting |
| Lee et al[^17], 2014 | N/A | N/A | Systemic lupus erythematosus (n = 2); Juvenile dermatomyositis (n = 1) | RUQ pain, nausea, vomiting |
| Sanches et al[^14], 2014 | 11 | F | Henoch-Schönlein purpura | Abdominal pain, jaundice |
| Ozkaya et al[^15], 2016 | 7 | M | Kawasaki disease (n = 28) | N/A (patients were included in a large case series of pediatric AAC) |

AAC: Acute acalculous cholecystitis; RUQ: Right upper quadrant.
have been associated with hepatitis A virus (HAV) and Epstein-Barr virus (EBV); however, only a minority of infected children develop AAC, which represents a rare complication.

As for EBV specifically, Yi et al.\textsuperscript{61} recently described 94 children affected by primary infection and undergoing abdominal ultrasonography. Around 25% of patients showed gallbladder abnormalities, particularly increased wall thickness; however, only a very small percentage (2%) fulfilled the diagnostic criteria for AAC. Interestingly, the authors noticed that EBV hepatitis seems to be more frequently associated with cholestasis abnormalities (e.g., increase of \(\gamma\)-glutamyl transpeptidase) compared to infections sustained by other herpes viruses (e.g., Cytomegalovirus).\textsuperscript{62,63} Unfortunately, the pathogenic mechanisms of viral AAC are not well known, but direct invasion or inflammation triggered by bile stasis may play a role. As for HAV, direct viral invasion of the gallbladder has been documented by Mourani et al.\textsuperscript{64} in a dated study. However, the local extension of the hepatic inflammatory process and/or elevated portal pressure (leading to edema of the gallbladder wall) have been speculated by some authors.\textsuperscript{65}

### Table 2 Reported cases of pediatric acute acalculous cholecystitis associated with specific infections (2000-2018)

| Ref. | Age (yr) | Sex | Comorbidity | Clinical manifestations |
|------|----------|-----|-------------|------------------------|
| Ashley et al.\textsuperscript{33}, 2000 | 4 | M | E. abortus | RUQ pain, fever, constipation, anorexia |
| Ciftci et al.\textsuperscript{66}, 2001 | 7 | M | HAV | Abdominal pain, fever, jaundice |
| Lo et al.\textsuperscript{67}, 2002 | 5 | M | Salmonella group D | Abdominal pain, fever, vomiting, diarrhea |
| Batra et al.\textsuperscript{68}, 2003 | 12 | M | S. aureus | RUQ pain, fever, jaundice, maculopapular rash |
| Garel et al.\textsuperscript{69}, 2003 | 4 | M | Salmonella spp. | Abdominal pain, fever, vomiting, diarrhea |
| Saha et al.\textsuperscript{70}, 2003 | 7 | F | P. falciparum | RUQ pain, fever |
| Axelrod et al.\textsuperscript{71}, 2007 | 3 | F | S. typhi | Abdominal pain, fever, vomiting |
| Kuntat et al.\textsuperscript{72}, 2007 | 8 and 9 | M | P. falciparum and P. vivax | RUQ pain, fever, jaundice, vomiting, anorexia |
| Lagone et al.\textsuperscript{73}, 2007 | 4 | F | EBV | RUQ pain, fever, jaundice, vomiting, anorexia |
| Anthonine-Milhomme et al.\textsuperscript{74}, 2007 | 7 | F | Plasmodium spp. | Abdominal pain, fever, diarrhea, jaundice |
| Prassouli et al.\textsuperscript{75}, 2007 | 13 | F | EBV | Abdominal pain, fever, vomiting, jaundice |
| Gora-Gebka et al.\textsuperscript{76}, 2008 | 9 and 4 | F | EBV + CMV and EBV | RUQ pain, fever, jaundice, enlargement of liver and spleen |
| Kumar et al.\textsuperscript{77}, 2008 | 3 | F | P. falciparum | Abdominal pain, fever, vomiting |
| Buyahia et al.\textsuperscript{78}, 2008 | 14 | M | HAV | Abdominal pain, vomiting, fever |
| Attikakos et al.\textsuperscript{79}, 2009 | 5 | M | EBV | Fever, jaundice, enlargement of liver and spleen |
| Sureshet et al.\textsuperscript{80}, 2009 | 2 | F | HAV | Abdominal pain, fever, vomiting |
| Souza et al.\textsuperscript{81}, 2009 | 16 | M | HAV | Abdominal pain, fever, vomiting |
| Arroud et al.\textsuperscript{82}, 2011 | 11 | M | HAV | Abdominal pain, fever, jaundice, vomiting |
| Herik et al.\textsuperscript{83}, 2011 | 9 | M | HAV | Abdominal pain, fever, jaundice, vomiting |
| Prashanth et al.\textsuperscript{84}, 2012 | 12 | F | HAV | Abdominal pain, vomiting |
| Newcombe et al.\textsuperscript{85}, 2013 | 9 | M | C. burnetti | N/A |
| Gnassingbe et al.\textsuperscript{86}, 2013 | 5-13 | 4 M, 2 F | S. typhi | Mainly abdominal pain, fever and vomiting |
| Poddighie et al.\textsuperscript{87}, 2014 | 7 | F | EBV | RUQ pain, fever, jaundice, liver enlargement |
| Kim et al.\textsuperscript{88}, 2014 | 10 | F | EBV | RUQ pain, fever, cervical lymphadenopathy |
| Fretzajos et al.\textsuperscript{89}, 2014 | 11 and 12 | F | EBV | Abdominal pain, fever, jaundice, hepatosplenomegaly |
| Strehele et al.\textsuperscript{90}, 2014 | 14 | F | EBV | Fever, RUQ pain, vomiting, anorexia, eyelid swelling |
| Suga K et al.\textsuperscript{91}, 2014 | 6 | F | EBV | Abdominal pain, fever, jaundice, epigastralgia |
| Alkoury et al.\textsuperscript{92}, 2015 | 15 | F | EBV | Abdominal pain, fever, vomiting |
| Pawlowska-Kamieniak et al.\textsuperscript{93}, 2015 | 17 | F | EBV | RUQ pain, fever, anorexia |
| Majdalani et al.\textsuperscript{94}, 2016 | 16 | F | EBV | Abdominal pain, fever, vomiting |
| Gomes et al.\textsuperscript{95}, 2016 | 3 | M | HHV-6 | Abdominal pain, vomiting, generalized maculo-papular skin rash |
| Ismael-Jaha et al.\textsuperscript{96}, 2018 | 1, 2, 4, 10 | F, F, M | Ascaris lumbricoides | Mainly fever, diarrhea, vomiting |
| Aguilera-Alonso et al.\textsuperscript{97}, 2018 | 5 | F | P. falciparum | Abdominal pain, fever, jaundice |

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HAV: Hepatitis A virus; HHV: Human herpes virus; RUQ: Right upper quadrant.

**CLINICAL AND DIAGNOSTIC ASPECTS**

In critically ill children who are not able to communicate appropriately, the diagnostic suspicion of AAC often derives from the onset of biochemical abnormalities suggesting cholestasis and liver dysfunction (e.g., plasma bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, \(\gamma\)-glutamyl transferase), in addition to fever and leukocytosis. Otherwise, the main clinical manifestation of AAC is abdominal pain (mild to severe), typically in the right upper quadrant, but sometimes diffuse. Fever, jaundice, vomiting and nausea can be variably present. Then, the clinical presentation is quite nonspecific, and the diagnosis can be challenging, especially when AAC is superimposed on acute hepatitis, whose laboratory findings can be similar because of concomitant intrahepatic cholestasis.\textsuperscript{6,66,67}

Therefore, AAC diagnosis necessarily relies on abdominal ultrasonography (US), which can reveal typical findings and diagnostic criteria, as follows: (1) Increased gallbladder wall thickness (> 3.5 mm); (2) pericholecystic fluid; (3) presence of mucosal membrane sludge; and (4) gallbladder distension. The presence
of at least two of these US criteria, in addition to the absence of gallstones, usually supports the diagnosis of AAC in the pediatric age\textsuperscript{[10]}. Thickening of the gallbladder wall is the most reliable single criterion, with a specificity of 90\% and 98.5\% using the cut-off of 3.0 mm and 3.5-mm wall thickness, respectively; moreover, the sensitivity was 100\% at 3.0 mm, but only 80\% at 3.5 mm. Therefore, especially in the presence of suggestive clinical and laboratory findings, gallbladder wall thickness of 3.5 mm or more by itself is generally accepted to be diagnostic\textsuperscript{[4,68]}. Among other imaging studies of the biliary tract, computerized tomography (CT) has been shown to be as accurate as US in the diagnosis of AAC, but it has some limitations due to radiological exposure, especially in the pediatric age. Moreover, CT is more expensive and cannot be performed bedside. However, CT should be used any time that other thoracic and/or abdominal diagnoses are under consideration and it is essential for the pre-operative assessment, if required (see below). The diagnostic criteria for AAC by CT are similar to those described for US\textsuperscript{[5,69,70]}. Other imaging studies such as technetium-labeled scintigraphy are quite problematic in children and, importantly, could be of limited value in the critical setting because of potential false positive results, due to prolonged fasting and concomitant liver disease\textsuperscript{[5,71]}.

**THERAPEUTIC MANAGEMENT**

AAC therapy in adults is substantially surgical, namely cholecystectomy. Indeed, a substantial rate of complications (e.g., empyema, perforation, gangrene) and the possibility of other underlying biliary diseases (malignancy, for instance) must be considered. Here, open or laparoscopic cholecystectomy provides both the possibility to review the gallbladder and the definitive treatment. Therefore, supportive therapy (e.g., analgesic drugs, intravenous hydration, parenteral nutrition) and antibiotics do not substitute the surgical approach, although they represent an essential part\textsuperscript{[60,72,73]}. However, the epidemiology and etiology of pediatric AAC is quite different from adults, as previously shown. Therefore, even the therapeutic management of AAC in children is different and, in particular, the frequency of the surgical approach is generally much lower than in adults or in children with ACC\textsuperscript{[6,74]}. In Table 3, we reported the conservative or interventional management in all available pediatric reports and small (uniform by etiology) case series\textsuperscript{[13-15,17,18,30,31,33,35-39,41,43-48,50,51,53-56,75-80]}. As already mentioned, this overview confirms that the management of AAC in children is often conservative. Most AAC children who finally required surgical management were affected with vasculitis or systemic bacterial infections or, interestingly, were patients who did not receive a final diagnosis, as the cause of AAC remained unknown.

In addition to all those case reports, there are some larger and/or heterogeneous case series that deserve to be discussed separately. Imagoglu et al\textsuperscript{[41]} described 12 children that developed AAC after previous abdominal surgery, during severe systemic infections or because of blunt abdominal trauma. Three of them required cholecystectomy because of the deterioration of their clinical conditions and US findings. Previously, in 1975 Tenberg et al\textsuperscript{[27]} reviewed 67 pediatric cases: 36 patients underwent cholecystectomy and 25 patients were treated by tube cholecystostomy; however, no analysis according to the etiology of AAC was provided in this study. Chirdan et al\textsuperscript{[81]} (from Nigeria) and Gnassingbé et al\textsuperscript{[80]} (form Togo) described two small case series of children developing AAC because of S. typhi infection, including sixteen (13 M, 3 F) and six (4 M, 2 F) patients, respectively. Interestingly, almost all children (except one in Chirdan’s study) required cholecystectomy by laparotomy as a final treatment, in addition to antibiotics, which supports the previous observations about the medical management in children.

Unfortunately, very few pediatric case series described AAC in critically ill children, but conservative management is strongly pursued, because these patients may not be able to safely sustain surgical (and anesthesiology) procedures. Huang et al\textsuperscript{[82]} retrospectively described their experience with 109 children with AAC (from 2000 to 2009) due to a variety of etiologies and highlighted some findings (including low platelet count, low hemoglobin value, presence of pericholecystic fluid/high sonographic score, hypofibrinogenemia and septic shock) as being predictive of poor outcome. However, all of their patients were treated non-operatively, including those affected with critical illnesses. They reported 15\% mortality rate (16 patients), and most of them (11 patients) developed AAC during sepsis (presented by a total of 27 patients), who then died of shock and multi-organ failure. Of course, it is not possible to make any conclusion about the most correct therapeutic management in these cases, but a timely surgical approach might be considered in selected situations, whenever the clinical condition allows it and before irreversible clinical deterioration. More recently, in a retrospective study (from 2004 to 2014) by Yi et al\textsuperscript{[10]} (including 131 children), only two patients (1.5\%) underwent cholecystectomy. Interestingly, no patients were admitted to the intensive care unit or presented with septic shock, but the indication for shifting from the conservative to the surgical approach was not specified. On the contrary, Rijcken\textsuperscript{[83]} performed cholecystectomy in all seven cases he described from his experience in a Malawi hospital, suggesting surgery as a preferential approach “in the African setting” and “in the very ill patient”. Only one child died post-operatively because of complicated sepsis. Recently, Schaefer CM retrospectively described ten critically ill and immune-compromised children who underwent percutaneous cholecystostomy. All patients were admitted to the intensive care unit; four children were hemodynamically unstable, three had multi-organ system failure, three developed renal failure and one was in septic shock. No patient developed procedure-related complications, but four patients died because of concomitant multi-organ failure. The surviving children.
Table 3  Main therapeutic approach in the reported cases of pediatric acute acalculous cholecystitis (2000-2018)

| Author et al. | Age (yr)/sex | Surgery | Antibiotic | Observations |
|---------------|--------------|---------|------------|--------------|
| Ashley et al. | 4-M          | -       | Ceftriaxone | Diagnosis through blood culture (initial antibiotic therapy with ampicillin, metronidazole and gentamicin) |
| Croteau et al. | 2-M          | Laparoscopic cholecystectomy | Second-generation cephalosporin | Removal of gallbladder after AAC recurrence |
| Lo et al. | 5-M          | Laparotomic cholecystectomy | Ceftriaxone | Removal of gallbladder for AAC complicated by empyema |
| Baтра et al. | 12-M         | Laparotomic cholecystectomy | Ampicillin/sulbactam | AAC developed for bacteriemia during osteomyelitis. |
| Saha et al. | 7-F          | -       | Ceftriaxone | Intravenous quinine as soon as definitive diagnosis was achieved |
| Basiratnia et al. | 10-M       | Laparotomic cholecystectomy | Ceftriaxone, metronidazole | High-dose prednisolone for 3 d. Surgical approach due to poor response (not specified) |
| Kurtiа et al. | 8-M          | -       | Ceftriaxone | Intraoperative quinine as soon as definitive diagnosis was achieved |
| Lagonna et al. | 4-F          | -       | -          | Only supportive therapy and close follow-up |
| Anthoine-Milhomme et al. | 7-F       | -       | Amoxicillin triamphenicol | Halofantrin was started upon diagnosis |
| Prassouli et al. | 13-F         | -       | Cefotaxime, tobramicin, metronidazole | Deflazacort 60 mg/m² |
| Shin et al. | 5-M          | -       | Ampicillin, cefotaxime | Deflazacort 60 mg/m² |
| Gора-Gebka et al. | 9-F-F | -       | Cefotaxime | |
| Bouyahia et al. | 14-M         | -       | Cefotaxime, gentamicin | |
| Suresh et al. | 2-F          | -       | -          | |
| Souza et al. | 16-M         | -       | -          | |
| Mendonca et al. | 12-F         | -       | -          | Concomitant SNC vasculitis findings: treated with high-dose prednisolone for 3 d. |
| McNaughton et al. | 14-M       | Laparoscopic cholecystectomy | Antibiotics (not specified) | |
| Karkera et al. | 11-M         | Laparotomic cholecystectomy | Antibiotics (not specified) | Both patients developed complicated (perforated) AAC |
| Arroud et al. | 11-M         | -       | Amoxicillin-clavulanic acid, gentamicin | |
| Herek et al. | 9-M          | -       | -          | |
| Pał K. et al. | 11-M         | Laparoscopic cholecystectomy | Antibiotics (not specified) | Emphysematous AAC associated with secondary appendicitis. Bile bacteriology revealed E. Coli and Enterooccus spp |
| Prashanth et al. | 12-F         | -       | -          | |
| Newcombe et al. | 9-M          | -       | Ampicillin, gentamicin, metronidazole | AAC as probable complication of infection-associated anti-phospholipid syndrome |
| Shihabuddin et al. | 10-F       | -       | Antibiotics (not specified) | |
| Kim et al. | 7-F          | -       | Cefotaxime | Patient coming from South-East Asia |
| Streble et al. | 14-F         | -       | Antibiotics (not specified) | |
| Sanchez et al. | 11-F         | -       | -          | high-dose prednisolone for 3 d |
| Suga et al. | 6-F          | -       | -          | Only supportive therapy |
| Alkoury et al. | 15-F         | -       | N/A        | |
| Pawlowska-Kamieniak et al. | 17-F      | -       | Antibiotics (not specified) | UDCA, analgesics, and relaxants |
| Muta et al. | 6-M          | Laparoscopic cholecystectomy | N/A | Case of eosinophilic cholecystitis without evidence of other eosinophilic disease |
| Majdalani et al. | 16-F         | -       | Ciprofloxacin, metronidazole | Concomitant nephrotic syndrome and EBV infection |
| Reda et al. | 2-M          | -       | Ceftriaxone | |
| Ozkaya et al. | 7-M          | Laparoscopic cholecystectomy | Antibiotics (not specified) | |
| Gomes et al. | 3-M          | -       | -          | |
benefited from percutaneous cholecystostomy, as three of them returned to normal gallbladder function, and this interventional procedure obviated cholecystectomy in the remaining three children until they were in such a clinical condition to endure it[50].

In summary, the current therapeutic management of AAC in children is mostly conservative, but hospital admission should be recommended in order to monitor the clinical and sonographic evolution in any individual case. Indeed, as mentioned previously, the study by Huang et al[51] reported a mortality rate of 15%, and more recently, Lu et al[52] showed that 29.25% of their pediatric patients needed the intensive care unit, and around 9.5% died. Again, concomitant sepsis was the main comorbidity in fatal AAC cases, but also other severe or lethal complications may develop[82,85].

Regardless of the etiology or the clinical condition, supportive therapy (analgesia, rehydration) is mandatory. Moreover, oral feeding is usually suspended until the amelioration in order to avoid stimulation of bile production, and the evacuation of gastric contents via nasogastric tube may be appropriate in some cases. Consequently, intravenous fluid replacement and parenteral nutrition is paramount[5,6]. Importantly, children must receive effective pain relief through nonsteroidal anti-inflammatory drugs, while opiates should be avoided. Finally, considering the frequent implication of infections in the development of AAC, antibiotic therapy should almost always be recommended and should include antibiotics against both gram-negative and anaerobic microorganisms, unless there is a different indication from the clinical situation and/or microbiological results. Antibiotic therapy is often prescribed even in AAC cases with a high suspicion of viral infection in order to prevent further complications, as described in Table 3. Most used antibiotics were a variable combination of a third generation cephalosporin, gentamicin and metronidazole[56,67]. Unfortunately, specific guidelines for pediatric cholecystitis are not available, and controlled studies are necessary to establish the most appropriate medical management of pediatric AAC.

CONCLUSION

AAC is a very heterogeneous disease, as it can arise in multiple clinical settings and can be sustained by different and/or overlapping pathogenic mechanisms. Importantly, the therapeutic management of pediatric AAC significantly differs from adults. Indeed, according to our literature review, most cases in children have been conservatively managed, while the surgical procedure (namely, laparotomic or laparoscopic cholecystectomy) was required in a minority of cases. Importantly, cholecystectomy was mostly performed in children developing AAC due to systemic bacterial infections or with no clear etiology. Indeed, those patients were more prone to complications (e.g., empyema, perforation), which represents the main indication for surgery in children. Most pediatric AAC cases were associated with viral infections (in particular, HAV and EBV), which showed lower rates of complications. In these cases, supportive management (including appropriate rehydration, temporary suspension of oral feeding and analgesic therapy) was sufficient. However, in almost all cases, wide-spectrum antibiotic therapy has been implemented despite the viral etiology. It is not always possible to immediately achieve a conclusive etiologic diagnosis, and that may be the reason why antibiotics are often or initially used. Therefore, in the management of pediatric AAC, pediatricians should be aware that many cases have a good prognosis and are often due to viral illnesses; however, if or until the viral nature is not completely evident, it is still recommended to start an appropriate antibiotic therapy. Moreover, children with AAC should always be admitted to the hospital to provide a tight clinical and sonographic follow-up, which can allow for quick response after complications that require a surgical approach.

REFERENCES

1 Elwood DR. Cholecystitis. Surg Clin North Am 2008; 88: 1241-1252, viii [PMID: 18992593 DOI: 10.1016/j.suc.2008.07.008]
2 Behar J, Mawe GM, Carey MC. Roles of cholesterol and bile salts in the pathogenesis of gallbladder hypomotility and inflammation: cholecystitis is not caused by cystic duct obstruction. Neurogastroenterol Motil 2013; 25: 283-290 [PMID: 23414509 DOI: 10.1111/nmo.12094]
3 Tsakayannis DE, Kozakewich HP, Lillehei CW. Acalculous cholecystitis in children. J Pediatr Surg 1996; 31: 127-130; discussion 130-131 [PMID: 8632265 DOI: 10.1016/S0022-3468(96)00334-6]
4 Murphy PB, Vogt KN, Winick-Ng J, McClure JA, Welk B, Jones SA. The increasing incidence of gallbladder disease in children: A 20year perspective. J Pediatr Surg 2016; 51: 748-752 [PMID: 26951963 DOI: 10.1016/j.jpedsurg.2016.02.017]
23 Naselli A, Bishop H, Walker S, Warris A. Neutropenic acute acalculous cholecystitis (AAC) in a 12-year-old boy with T-acute lymphoblastic leukemia successfully managed with conservative treatment. *Pediatr Hematol Oncol* 2017; 34: 24-28 [PMID: 28985529 DOI: 10.1080/08880012.2016.1260341]

24 Pal K. Laparoscopy in the management of emphysematous cholecystitis and secondary appendicitis in an 11-year-old child with insulin-dependent diabetes mellitus. *Afr J Paediatr Surg* 2011; 8: 211-214 [PMID: 22005368 DOI: 10.4103/1893-6725.86665]

25 Khuroo MS, Rather AA, Khuroo NS, Khuroo MS. Hepatobiliary and pancreatic ascarisiasis. *World J Gastroenterol* 2016; 22: 7507-7517 [PMID: 27622723 DOI: 10.3748/wjg.v22.i33.7507]

26 Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, Finlay BB. Salmonella infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute typhoid fever. *J Infect Dis* 2009; 200: 1703-1713 [PMID: 19852670 DOI: 10.1086/666608]

27 Ternberg JL, Jeating JP. Acute acalculous cholecystitis. Complication of other illnesses in childhood. *Arch Surg* 1975; 110: 543-547 [PMID: 11309999 DOI: 10.1001/archsurg.1975.01650060066011]

28 Ashley D, Vade A, Challapalli M. Brucellosis with acute acalculous cholecystitis. *Pediatr Infect Dis J* 2000; 19: 1112-1113 [PMID: 11099103 DOI: 10.1097/00006454-200011000-00024]

29 Ciftci AO, Kamak I, Tanyel FC. The association of hepatitis A virus infection, acalculous cholecystitis, and blunt abdominal trauma: a diagnostic challenge. *J Pediatr Gastroenterol Nutr* 2001; 32: 92-94 [PMID: 11763344 DOI: 10.1097/00005176-200101000-00024]

30 Lo WT, Wang CC, Chu ML. Acute septicaemic acalculous cholecystitis complicated by empyema caused by Salmonella group D in a previously healthy child. *Eur J Pediatr Surg* 2002; 161: 575-577 [PMID: 12424580 DOI: 10.1067/s0003-9846-001-00106-1]

31 Batra V, Ang JY, Asmar BL. Staphylococcal acalculous cholecystitis in a child. *South Med J* 2003; 96: 206-208 [PMID: 12630651 DOI: 10.1097/01.SMJ.0000051277.81177.AA]

32 Garell L, Luecaya J, Piqueras J. Acute acalculous cholecystitis owing to salmonella sepsis. *Pediatr Radiol* 2003; 33: 905-906 [PMID: 14574527 DOI: 10.1007/s00247-003-0990-x]

33 Saha A, Batra P, Vilhekar KY, Chaturvedi P. Acute acalculous cholecystitis in a child with Plasmodium falciparum malaria. *Ann Trop Paediatr* 2005; 25: 141-142 [PMID: 15949204 DOI: 10.1176/146332850X45755]

34 Axelrod D, Karakas SP. Acalculous cholecystitis and abscess as a manifestation of typhoid fever. *Pediatr Radiol* 2007; 37: 237-241 [PMID: 17099115 DOI: 10.1007/s00247-007-0437-3]

35 Karttis VS, Kohli U. Acute acalculous cholecystitis associated with malarial infection in children: report of two cases. *J Trop Pediatr* 2003; 5: 59-61 [PMID: 17135216 DOI: 10.1093/tropej/fm055]

36 Lagoa E, Sharifi F, Voutsioti A, Mavri A, Markouri M, Attilakos A. Epstein-Barr virus infection, acute cholecystitis, and blunt abdominal trauma: a diagnostic challenge. *Pediatr Radiol* 2003; 33: 905-906 [PMID: 14574527 DOI: 10.1007/s00247-003-0990-x]

37 Ghera AS, Meka M, Tresoldi M, Licari A, Marseglia GL. Acalculous Acute Cholecystitis in 3 Patients with Malaria. *Pediatr Radiol* 2003; 33: 905-906 [PMID: 14574527 DOI: 10.1007/s00247-003-0990-x]

38 Menendez A, Arena ET, Guttman JA, Thorson L, Vallance BA, Vogl W, Finlay BB. Salmonella infection of gallbladder epithelial cells drives local inflammation and injury in a model of acute typhoid fever. *J Infect Dis* 2009; 200: 1703-1713 [PMID: 19852670 DOI: 10.1086/666608]

39 Ternberg JL, Keating JP. Acute acalculous cholecystitis. Complication of other illnesses in childhood. *Arch Surg* 1975; 110: 543-547 [PMID: 11309999 DOI: 10.1001/archsurg.1975.01650060066011]

40 Ashley D, Vade A, Challapalli M. Brucellosis with acute acalculous cholecystitis. *Pediatr Infect Dis J* 2000; 19: 1112-1113 [PMID: 11099103 DOI: 10.1097/00006454-200011000-00024]

41 Ciftci AO, Kamak I, Tanyel FC. The association of hepatitis A virus infection, acalculous cholecystitis, and blunt abdominal trauma: a diagnostic challenge. *J Pediatr Gastroenterol Nutr* 2001; 32: 92-94 [PMID: 11763344 DOI: 10.1097/00005176-200101000-00024]

42 Lo WT, Wang CC, Chu ML. Acute septicaemic acalculous cholecystitis complicated by empyema caused by Salmonella group D in a previously healthy child. *Eur J Pediatr Surg* 2002; 161: 575-577 [PMID: 12424580 DOI: 10.1067/s0003-9846-001-00106-1]

43 Garell L, Luecaya J, Piqueras J. Acute acalculous cholecystitis owing to salmonella sepsis. *Pediatr Radiol* 2003; 33: 905-906 [PMID: 14574527 DOI: 10.1007/s00247-003-0990-x]

44 Saha A, Batra P, Vilhekar KY, Chaturvedi P. Acute acalculous cholecystitis in a child with Plasmodium falciparum malaria. *Ann Trop Paediatr* 2005; 25: 141-142 [PMID: 15949204 DOI: 10.1176/146332850X45755]

45 Axelrod D, Karakas SP. Acalculous cholecystitis and abscess as a manifestation of typhoid fever. *Pediatr Radiol* 2007; 37: 237-241 [PMID: 17099115 DOI: 10.1007/s00247-007-0437-3]

46 Karttis VS, Kohli U. Acute acalculous cholecystitis associated with malarial infection in children: report of two cases. *J Trop Pediatr* 2003; 5: 59-61 [PMID: 17135216 DOI: 10.1093/tropej/fm055]

47 Lagoa E, Sharifi F, Voutsioti A, Mavri A, Markouri M, Attilakos A. Epstein-Barr virus infection, acute cholecystitis, and blunt abdominal trauma: a diagnostic challenge. *Pediatr Radiol* 2003; 33: 905-906 [PMID: 14574527 DOI: 10.1007/s00247-003-0990-x]
two year old. *JSLS* 2001; 5: 183-185 [PMID: 11394434]

76 **McNaughton C**, Morrow S, Cico SJ. Acalculous cholecystitis in a healthy 4-year-old boy. *Am J Emerg Med* 2011; 29: 962.e1-962.e2 [PMID: 20970290 DOI: 10.1016/j.ajem.2010.08.022]

77 **Karkera PJ**, Sandlas G, Ranjan R, Gupta A, Kothari P. Acute acalculous cholecystitis causing gall bladder perforation in children. *J Indian Assoc Pediatr Surg* 2010; 15: 139-141 [PMID: 21170198 DOI: 10.4103/0971-9261.72439]

78 **Muta Y**, Odaka A, Inoue S, Komagome M, Beck Y, Tamura M, Arai E. Acalculous cholecystitis with eosinophilic infiltration. *Paediatr Int* 2015; 57: 788-791 [PMID: 26315204 DOI: 10.1111/ped.12650]

79 **Reda D**, Huici M, Ricart S, Vila J, Fortuny C, Alsina L. Acalculous cholecystitis and nephrotic syndrome complicating Epstein-Barr virus primary infection. *Paediatr Int Child Health* 2017; 37: 74-77 [PMID: 27077634 DOI: 10.1080/20469047.2015.1135561]

80 **Ng JY**, Gu J. Conservative Management of Acalculous Cholecystitis in a Seven-year-old Child. *Cureus* 2018; 10: e2092 [PMID: 29564197 DOI: 10.7759/cureus.2092]

81 **Chirdan LB**, Iya D, Ramyil VM, Sule AZ, Ugbu BT. Acalculous cholecystitis in Nigerian children. *Pediatr Surg Int* 2003; 19: 65-67 [PMID: 12721727 DOI: 10.1007/s00383-002-0826-z]

82 **Huang SC**, Yang YJ. Septic shock and hypotension menemia predict a fatal outcome in childhood acute acalculous cholecystitis. *J Pediatr Gastroenterol Nutr* 2011; 53: 548-552 [PMID: 21832944 DOI: 10.1097/MPG.0b013e318230c380]

83 **Rijcken JM**. Acalculous cholecystitis in children. *East Cent Afr J Surg* 2000; 5: 31-34

84 **Schaefder CM**, Towbin RB, Aria DJ, Kaye RD. Safety and effectiveness of percutaneous cholecystostomy in critically ill children who are immune compromised. *Pediatr Radiol* 2016; 46: 1040-1045 [PMID: 26886916 DOI: 10.1007/s00247-016-3562-6]

85 **Lu YA**, Chiu CH, Kong MS, Wang HJ, Chao HC, Chen CC. Risk factors for poor outcomes of children with acute acalculous cholecystitis. *Pediatr Neonatol* 2017; 58: 497-503 [PMID: 2849592 DOI: 10.1016/j.pnedeo.2016.12.005]

86 **Gomi H**, Solomin JS, Schlossberg D, Okamoto K, Takada T, Strasberg SM, Ukai T, Endo I, Iwashita Y, Hibi T, Pitt HA, Matsunaga N, Takamori Y, Umezawa A, Asai K, Suzuki K, Han HS, Hwang TL, Mori Y, Yoon YS, Huang WS, Belli G, Dervenis C, Yokoe M, Kiriyama S, Itoi T, Jagannath P, Garden OJ, Miura F, de Santibañes E, Shihata S, Noguchi Y, Wada K, Honda G, Supe AN, Yoshida M, Mayumi T, Gouma DJ, Deziel DJ, Liu KH, Su CH, Chan ACW, Yoon DS, Choi IS, Jonas E, Chen XP, Fan ST, Ker CG, Giménez ME, Kitano S, Inomata M, Mukai S, Higuchi R, Hirata K, Inui K, Sumiyama Y, Yamamoto M. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci* 2018; 25: 3-16 [PMID: 29090866 DOI: 10.1002/jhbp.518]

87 **van Dijk AH**, de Reuver PR, Tasma TN, van Dieren S, Hugh TJ, Boermeester MA. Systematic review of antibiotic treatment for acute calcualous cholecystitis. *Br J Surg* 2016; 103: 797-811 [PMID: 27027851 DOI: 10.1002/bjs.10146]

**P- Reviewer**: Horesh N, Kim JS  
**S- Editor**: Wang XJ  
**L- Editor**: Filipodia  
**E- Editor**: Bian YN
